Build Your Comparison

Side-by-side financial analysis
NCRA logo
NCRA
LIXT logo
LIXT
JPM logo
JPM
BAC logo
BAC
ONCY logo
ONCY
Try popular comparisons:

Stock Comparison

NCRA vs LIXT vs JPM vs BAC vs ONCY

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NCRA
Nocera, Inc.

Packaged Foods

Consumer DefensiveNASDAQ • TW
Market Cap$2M
5Y Perf.-96.3%
LIXT
Lixte Biotechnology Holdings, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$76M
5Y Perf.-77.0%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$842.21B
5Y Perf.+142.8%
BAC
Bank of America Corporation

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$409.69B
5Y Perf.+81.6%
ONCY
Oncolytics Biotech Inc.

Biotechnology

HealthcareNASDAQ • CA
Market Cap$94M
5Y Perf.-66.6%

NCRA vs LIXT vs JPM vs BAC vs ONCY — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NCRA logoNCRA
LIXT logoLIXT
JPM logoJPM
BAC logoBAC
ONCY logoONCY
IndustryPackaged FoodsBiotechnologyBanks - DiversifiedBanks - DiversifiedBiotechnology
Market Cap$2M$76M$842.21B$409.69B$94M
Revenue (TTM)$11M$0.00$270.79B$188.75B$0.00
Net Income (TTM)$-4M$-7M$58.03B$30.63B$-35M
Gross Margin1.4%58.6%55.4%
Operating Margin-25.2%27.7%18.5%
Forward P/E14.0x12.1x
Total Debt$7M$664K$751.15B$365.90B$773K
Cash & Equiv.$8M$5M$469.32B$231.84B$7M

NCRA vs LIXT vs JPM vs BAC vs ONCYLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NCRA
LIXT
JPM
BAC
ONCY
StockJan 21Jun 26Return
Nocera, Inc. (NCRA)1003.7-96.3%
Lixte Biotechnology… (LIXT)10023.0-77.0%
JPMorgan Chase & Co. (JPM)100242.8+142.8%
Bank of America Cor… (BAC)100181.6+81.6%
Oncolytics Biotech … (ONCY)10033.4-66.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: NCRA vs LIXT vs JPM vs BAC vs ONCY

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JPM leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. Lixte Biotechnology Holdings, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. BAC also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
NCRA
Nocera, Inc.
The Consumer Defensive Pick

NCRA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: consumer defensive exposure
LIXT
Lixte Biotechnology Holdings, Inc.
The Defensive Pick

LIXT is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 1.19, Low D/E 6.1%, current ratio 3.88x
  • 152.8% revenue growth vs ONCY's -65.0%
  • +407.2% vs NCRA's -83.7%
Best for: sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 14.6%, EPS growth 21.7%
  • 435.6% 10Y total return vs BAC's 323.5%
  • NIM 2.3% vs BAC's 1.8%
  • 21.6% margin vs NCRA's -34.0%
Best for: growth exposure and long-term compounding
BAC
Bank of America Corporation
The Banking Pick

BAC ranks third and is worth considering specifically for income & stability and valuation efficiency.

  • Dividend streak 12 yrs, beta 0.89, yield 2.4%
  • PEG 0.79 vs JPM's 1.08
  • Beta 0.89, yield 2.4%, current ratio 0.42x
  • Better valuation composite
Best for: income & stability and valuation efficiency
ONCY
Oncolytics Biotech Inc.
The Healthcare Pick

Among these 5 stocks, ONCY doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthLIXT logoLIXT152.8% revenue growth vs ONCY's -65.0%
ValueBAC logoBACBetter valuation composite
Quality / MarginsJPM logoJPM21.6% margin vs NCRA's -34.0%
Stability / SafetyBAC logoBACBeta 0.89 vs NCRA's 1.68, lower leverage
DividendsJPM logoJPM1.6% yield, 15-year raise streak, vs BAC's 2.4%, (3 stocks pay no dividend)
Momentum (1Y)LIXT logoLIXT+407.2% vs NCRA's -83.7%
Efficiency (ROA)JPM logoJPM1.3% ROA vs ONCY's -275.4%

NCRA vs LIXT vs JPM vs BAC vs ONCY — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NCRANocera, Inc.

Segment breakdown not available.

LIXTLixte Biotechnology Holdings, Inc.

Segment breakdown not available.

JPMJPMorgan Chase & Co.
FY 2024
Consumer & Community Banking
40.3%$71.5B
Commercial And Investment Bank
39.5%$70.1B
Asset and Wealth Management Segment
12.2%$21.6B
Segment Reporting, Reconciling Item, Corporate Nonsegment
9.8%$17.4B
Segment Reconciling Items
-1.7%$-3,037,000,000
BACBank of America Corporation
FY 2024
Loans and Leases
32.2%$62.0B
other interest income
14.7%$28.3B
Debt securities
13.5%$26.0B
Federal funds sold and securities borrowed or purchased under agreements to resell
10.3%$19.9B
Investment And Brokerage Services
9.2%$17.8B
Market making and similar activities
6.7%$13.0B
Trading account assets
5.4%$10.4B
Other (4)
7.8%$15.1B
ONCYOncolytics Biotech Inc.

Segment breakdown not available.

NCRA vs LIXT vs JPM vs BAC vs ONCY — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGONCY

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 5 comparable metrics.

JPM and ONCY operate at a comparable scale, with $270.8B and $0 in trailing revenue. JPM is the more profitable business, keeping 21.6% of every revenue dollar as net income compared to NCRA's -34.0%.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ONCY logoONCYOncolytics Biotec…
RevenueTrailing 12 months$11M$0$270.8B$188.8B$0
EBITDAEarnings before interest/tax-$3M-$7M$81.3B$36.6B-$31M
Net IncomeAfter-tax profit-$4M-$7M$58.0B$30.6B-$35M
Free Cash FlowCash after capex-$3M-$4M-$119.7B$12.6B-$29M
Gross MarginGross profit ÷ Revenue+1.4%+58.6%+55.4%
Operating MarginEBIT ÷ Revenue-25.2%+27.7%+18.5%
Net MarginNet income ÷ Revenue-34.0%+21.6%+16.2%
FCF MarginFCF ÷ Revenue-26.9%-15.5%+6.7%
Rev. Growth (YoY)Latest quarter vs prior year-49.8%
EPS Growth (YoY)Latest quarter vs prior year-3.9%+37.9%+16.0%+18.3%-39.2%
JPM leads this category, winning 3 of 5 comparable metrics.

Valuation Metrics

Evenly matched — NCRA and BAC each lead in 2 of 6 comparable metrics.

At 14.1x trailing earnings, BAC trades at a 11% valuation discount to JPM's 15.8x P/E. Adjusting for growth (PEG ratio), BAC offers better value at 0.92x vs JPM's 1.22x — a lower PEG means you pay less per unit of expected earnings growth.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ONCY logoONCYOncolytics Biotec…
Market CapShares × price$2M$76M$842.2B$409.7B$94M
Enterprise ValueMkt cap + debt − cash$2M$72M$1.12T$543.8B$89M
Trailing P/EPrice ÷ TTM EPS-0.84x-5.56x15.82x14.09x-2.83x
Forward P/EPrice ÷ next-FY EPS est.14.03x12.07x
PEG RatioP/E ÷ EPS growth rate1.22x0.92x
EV / EBITDAEnterprise value multiple13.54x14.85x
Price / SalesMarket cap ÷ Revenue0.22x3.11x2.17x
Price / BookPrice ÷ Book value/share1.09x30.91x2.61x1.34x
Price / FCFMarket cap ÷ FCF32.48x
Evenly matched — NCRA and BAC each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

JPM leads this category, winning 5 of 9 comparable metrics.

JPM delivers a 16.1% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-102 for ONCY. LIXT carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to NCRA's 3.31x. On the Piotroski fundamental quality scale (0–9), BAC scores 7/9 vs ONCY's 1/9, reflecting strong financial health.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ONCY logoONCYOncolytics Biotec…
ROE (TTM)Return on equity-132.0%-113.2%+16.1%+10.1%-102.5%
ROA (TTM)Return on assets-52.5%-96.3%+1.3%+0.9%-2.8%
ROICReturn on invested capital-70.0%-121.5%+5.4%+3.2%
ROCEReturn on capital employed-35.9%-83.5%+8.2%+4.2%-5.1%
Piotroski ScoreFundamental quality 0–934571
Debt / EquityFinancial leverage3.31x0.06x2.18x1.21x
Net DebtTotal debt minus cash-$697,307-$4M$281.8B$134.1B-$6M
Cash & Equiv.Liquid assets$8M$5M$469.3B$231.8B$7M
Total DebtShort + long-term debt$7M$664,491$751.1B$365.9B$772,509
Interest CoverageEBIT ÷ Interest expense-1217.29x0.74x0.44x
JPM leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $20,251 today (with dividends reinvested), compared to $343 for NCRA. Over the past 12 months, LIXT leads with a +407.2% total return vs NCRA's -83.7%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.0% vs NCRA's -51.6% — a key indicator of consistent wealth creation.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ONCY logoONCYOncolytics Biotec…
YTD ReturnYear-to-date-80.3%+82.3%-3.1%-2.8%-14.7%
1-Year ReturnPast 12 months-83.7%+407.2%+21.5%+24.4%+151.3%
3-Year ReturnCumulative with dividends-88.7%+5.6%+135.5%+99.5%-49.0%
5-Year ReturnCumulative with dividends-96.6%-77.3%+102.5%+36.1%-72.0%
10-Year ReturnCumulative with dividends-97.4%-22.2%+435.6%+323.5%-79.6%
CAGR (3Y)Annualised 3-year return-51.6%+1.8%+33.0%+25.9%-20.1%
JPM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

BAC leads this category, winning 2 of 2 comparable metrics.

BAC is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than NCRA's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BAC currently trades 93.5% from its 52-week high vs NCRA's 7.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ONCY logoONCYOncolytics Biotec…
Beta (5Y)Sensitivity to S&P 5001.68x1.19x0.95x0.89x1.24x
52-Week HighHighest price in past year$2.40$7.50$337.25$57.55$1.51
52-Week LowLowest price in past year$0.16$0.64$260.31$43.66$0.33
% of 52W HighCurrent price vs 52-week peak+7.0%+93.3%+92.6%+93.5%+55.4%
RSI (14)Momentum oscillator 0–10040.869.858.465.446.2
Avg Volume (50D)Average daily shares traded7.2M89K7.1M32.4M1.3M
BAC leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — JPM and BAC each lead in 1 of 2 comparable metrics.

Analyst consensus: JPM as "Buy", BAC as "Buy", ONCY as "Buy". Consensus price targets imply 13.6% upside for BAC (target: $61) vs 8.5% for JPM (target: $339). For income investors, BAC offers the higher dividend yield at 2.35% vs JPM's 1.64%.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ONCY logoONCYOncolytics Biotec…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$338.78$61.13
# AnalystsCovering analysts615410
Dividend YieldAnnual dividend ÷ price+1.6%+2.4%
Dividend StreakConsecutive years of raises01512
Dividend / ShareAnnual DPS$5.13$1.27
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+3.4%+5.2%0.0%
Evenly matched — JPM and BAC each lead in 1 of 2 comparable metrics.
Key Takeaway

JPM leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BAC leads in 1 (Risk & Volatility). 2 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 3 of 6 categories
Loading custom metrics...

NCRA vs LIXT vs JPM vs BAC vs ONCY: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NCRA or LIXT or JPM or BAC or ONCY a better buy right now?

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 14. 6% revenue growth year-over-year, versus -35. 2% for Nocera, Inc. (NCRA). Bank of America Corporation (BAC) offers the better valuation at 14. 1x trailing P/E (12. 1x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NCRA or LIXT or JPM or BAC or ONCY?

On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.

1x versus JPMorgan Chase & Co. at 15. 8x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Bank of America Corporation wins at 0. 79x versus JPMorgan Chase & Co. 's 1. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — NCRA or LIXT or JPM or BAC or ONCY?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +102. 5%, compared to -96. 6% for Nocera, Inc. (NCRA). Over 10 years, the gap is even starker: JPM returned +435. 6% versus NCRA's -97. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NCRA or LIXT or JPM or BAC or ONCY?

By beta (market sensitivity over 5 years), Bank of America Corporation (BAC) is the lower-risk stock at 0.

89β versus Nocera, Inc. 's 1. 68β — meaning NCRA is approximately 88% more volatile than BAC relative to the S&P 500. On balance sheet safety, Lixte Biotechnology Holdings, Inc. (LIXT) carries a lower debt/equity ratio of 6% versus 3% for Nocera, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NCRA or LIXT or JPM or BAC or ONCY?

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 14. 6% versus -35. 2% for Nocera, Inc. (NCRA). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 21. 7% year-over-year, compared to -11. 1% for Nocera, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NCRA or LIXT or JPM or BAC or ONCY?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 21. 6% net margin versus -25. 7% for Nocera, Inc. — meaning it keeps 21. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 27. 7% versus -22. 3% for NCRA. At the gross margin level — before operating expenses — JPM leads at 58. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NCRA or LIXT or JPM or BAC or ONCY more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Bank of America Corporation (BAC) is the more undervalued stock at a PEG of 0. 79x versus JPMorgan Chase & Co. 's 1. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 1x forward P/E versus 14. 0x for JPMorgan Chase & Co. — 2. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BAC: 13. 6% to $61. 13.

08

Which pays a better dividend — NCRA or LIXT or JPM or BAC or ONCY?

In this comparison, BAC (2.

4% yield), JPM (1. 6% yield) pay a dividend. NCRA, LIXT, ONCY do not pay a meaningful dividend and should not be held primarily for income.

09

Is NCRA or LIXT or JPM or BAC or ONCY better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), 1. 6% yield, +435. 6% 10Y return). Nocera, Inc. (NCRA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +435. 6%, NCRA: -97. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NCRA and LIXT and JPM and BAC and ONCY?

These companies operate in different sectors (NCRA (Consumer Defensive) and LIXT (Healthcare) and JPM (Financial Services) and BAC (Financial Services) and ONCY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NCRA is a small-cap quality compounder stock; LIXT is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; BAC is a large-cap deep-value stock; ONCY is a small-cap quality compounder stock. JPM, BAC pay a dividend while NCRA, LIXT, ONCY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.